What is Fortress Biotech, Inc. (FBIOP)?

Fortress Biotech, Inc. (FBIOP) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of FBIOP?

The current price of FBIOP is $15.59. Prices are updated in real time on Stocks360.

What is FBIOP's price-to-earnings (PE) ratio?

FBIOP's trailing twelve-month PE ratio is 0.61, based on current price and earnings per share data available on Stocks360.

What is FBIOP's market capitalization?

FBIOP's market capitalization is $64,214,618.00, placing it in the small-cap tier.

Fortress Biotech, Inc. (FBIOP)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$15.59

Market Cap

$64.21M

PE (TTM)

0.61

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.21

Day Range

$15.52 – $16.15

52-wk Range

$6.27 – $21.43

Avg Volume

N/A

Volume

17.90K

Fortress Biotech, Inc. (FBIOP) is a publicly traded company in the Healthcare sector. Latest price: $15.59. Market cap $64.21M. Trailing PE 0.61. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $6.86 2026-10-29 · $15.59 (+127.26%)

Earnings

Most Recent

Aug 13, 2026

EPS $-0.08 vs est. $-0.20

Beat by $0.12

Next Earnings

Nov 16, 2026

EPS estimate $-0.27

Proprietary Signals

Signal snapshot temporarily unavailable.

About Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; a…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	0.61×
P/S (TTM)	0.97×
P/B	0.39×
PEG	0.00×
P/FCF (TTM)	0.53×
EV / EBITDA	-0.41×
EV / Sales	-0.95×
Earnings Yield	176.56%
Free Cash Flow Yield	188.66%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$65.09M
Net Income (TTM)	$117.77M
Free Cash Flow (TTM)	$134.52M
Net Debt	-$131.79M
Working Capital	$183.49M
Gross Margin	62.53%
Operating Margin	-42.86%
Net Margin	163.32%
Return on Equity	103.52%
Return on Invested Capital	-10.85%